Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8

European Journal of Haematology

Volumn 95, Issue 3, 2015, Pages 230-238

  Hosokawa, Kohei ^a   Sugimori, Naomi ^a   Katagiri, Takamasa ^a   Sasaki, Yumi ^a   Saito, Chizuru ^a   Seiki, Yu ^a   Mochizuki, Kanako ^a   Yamazaki, Hirohito ^a   Takami, Akiyoshi ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Bone marrow failure; GPI AP cells; Immunosuppressive therapy; Trisomy 8

Indexed keywords

CYCLOSPORIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; METENOLONE ACETATE; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHILD; EVENT FREE SURVIVAL; FEMALE; GRANULOCYTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCHOOL CHILD; SURVIVAL RATE; TREATMENT RESPONSE; TRISOMY 8; VERY ELDERLY; YOUNG ADULT; BONE MARROW; CHROMOSOME 8; DEFICIENCY; GENETICS; HEMOGLOBINURIA, PAROXYSMAL; INCIDENCE; METABOLISM; MORTALITY; PATHOLOGY; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRISOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GPI-LINKED PROTEINS; GRANULOCYTES; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRISOMY; YOUNG ADULT;

EID: 84938982037     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12484     Document Type: Article

References (34)

1. Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE, Thomas ED. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987;15:1134-9.
2. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008;87:515-26.
3. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002;99:3129-35.
4. Bernasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol 2007;137:193-205.
5. Kim SY, Lee JW, Lee SE, et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. Genes Chromosom Cancer 2010;49:844-50.
6. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-9.
7. Gupta V, Brooker C, Tooze JA, Yi QL, Sage D, Turner D, Kangasabapathy P, Marsh JC. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol 2006;134:95-9.
8. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 1996;81:418-22.
9. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007;110:4385-95.
10. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
11. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, Lu J, Basu A, Barrett AJ, Young NS. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005;106:841-51.
12. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, Kumar MS, Rosenfeld S, Young NS. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999;131:401-8.
13. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002;100:3897-902.
14. Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, Raza A, Woda BA. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 2009;94:29-37.
15. Araten DJ, Swirsky D, Karadimitris A, et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2001;115:360-8.
16. Hosokawa K, Katagiri T, Sugimori N, Ishiyama K, Sasaki Y, Seiki Y, Sato-Otsubo A, Sanada M, Ogawa S, Nakao S. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation. Haematologica 2012;97:1845-1849.
17. Sloand EM, Fuhrer M, Keyvanfar K, Mainwaring L, Maciejewski J, Wang Y, Johnson S, Barrett AJ, Young NS. Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive. Br J Haematol 2003;123:173-6.
18. Parlier V, Tiainen M, Beris P, Miescher PA, Knuutila S, Jotterand Bellomo M. Trisomy 8 detection in granulomonocytic, erythrocytic and megakaryocytic lineages by chromosomal in situ suppression hybridization in a case of refractory anaemia with ringed sideroblasts complicating the course of paroxysmal nocturnal haemoglobinuria. Br J Haematol 1992;81:296-304.
19. Longo L, Bessler M, Beris P, Swirsky D, Luzzatto L. Myelodysplasia in a patient with pre-existing paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease. Br J Haematol 1994;87:401-3.
20. Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res 2008;32:553-8.
21. International Standing Committee on Human Cytogenetic Nomenclature, Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: An International System for Human Cytogenetic Nomenclature. Basel; Unionville, CT: Karger, 2009.
22. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
23. Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol 1990;12:411-24.
24. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, Mizoguchi H, Omine M, Nakao S. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-14.
25. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999;96:5209-14.
26. Sugimori C, Mochizuki K, Qi Z, Sugimori N, Ishiyama K, Kondo Y, Yamazaki H, Takami A, Okumura H, Nakao S. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009;147:102-12.
27. Kulagin A, Golubovskaya I, Ganapiev A, et al. Prognostic value of minor PNH clones in aplastic anaemia patients treated with ATG-based immunosuppression: results of a two-centre prospective study. Bone Marrow Transplant 2011;46:S83-4.
28. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.
29. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-458.
30. Seiki Y, Sasaki Y, Hosokawa K, Saito C, Sugimori N, Yamazaki H, Takami A, Nakao S. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica 2013;98:901-907.
31. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, Young NS. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007;109:2399-405.
32. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011;118:6601-9.
33. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
34. Saumell S, Florensa L, Luno E, et al. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. Br J Haematol 2012;159:311-21.